about
Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatmentEndothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptorTreatment of refractory chronic GVHD with rituximab: a GITMO study.Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patientsMucorales-Specific T Cells in Patients with Hematologic Malignancies.Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis.Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation.BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi.Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised pEstablishment and characterization of a human IgA-kappa-secreting plasma cell line (MT3).Persistent carriage and infection by multidrug-resistant Escherichia coli ST405 producing NDM-1 carbapenemase: report on the first Italian cases.Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center stuAcute appendicitis in adult neutropenic patients with hematologic malignancies.Human herpesvirus 8 (HHV8) infection and related diseases in Italian transplant cohorts.Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6.Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.Prevalence of human herpesvirus-6 chromosomal integration (CIHHV-6) in Italian solid organ and allogeneic stem cell transplant patients.Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical studyReduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myelomaDetection of Fusarium-specific T cells in hematologic patients with invasive fusariosisKappa light chain gene rearrangement in a T-cell lymphomaThe effect of cytosine-arabinoside treatment on the overexpression of c-myc protooncogene in a case of prolymphocytic leukemiaT-cell receptor genes expression in B-cell leukaemiasStudy of the levels of expression of two oncogenes, c-myc and c-myb, in acute and chronic leukemias of both lymphoid and myeloid lineageOccurrence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia
P50
Q28217057-30175D88-A88A-4E2F-A7AC-3F3715B40900Q28539394-609D2EB9-268B-4688-96A3-A57CF650BA43Q33375484-C29F972A-9E6F-4D9C-A2ED-D5629EF29FCEQ34984670-EE131B15-8181-4906-8577-ABCA6B92287BQ35922089-862C3344-553A-47FD-800E-A73F05469708Q36006453-9F600E06-10E3-46E7-A55A-824C79DE35A5Q36715966-71D7C85A-6522-4F17-ACEE-21992D49950FQ36967153-93D155B4-44E5-4D63-931F-63125F22AC1DQ38030534-21188216-2A5B-4925-929F-0A388846B71DQ38930292-82422C21-BCBC-45AF-9ACA-241AB2887A63Q39122060-F24318AF-2BDC-4112-96D7-663DBF1BE968Q40843566-9B886D43-D1EC-4AF7-818A-CE405F27BDF5Q40856883-1555CA4A-2ABD-49D1-B085-962633F59101Q41525599-1BCCFE54-27AA-4247-992C-88B29C2F2CA7Q42781523-45D3F091-116A-4366-BEAB-B5DAAF2BBBD3Q42820727-B3ACD312-B409-45EE-ABA1-351D84EF81D2Q42850229-1A0FFA96-EF84-4DC7-B875-0E251F19BE54Q42910824-FCE2D751-2129-4A3B-9D18-FC2185879563Q43427378-621A115A-3C4B-4ECA-A4FF-0A07BEB2EE95Q43645374-161A5B2A-3244-439B-BD2C-7C6BB4D9F7A0Q43653484-C0E23279-44AF-4B9D-8D75-D879579C0B80Q44786116-45D92C7A-123C-4BF0-99B0-88BC899D7258Q44915322-FF905D9E-B6CC-42E0-9020-AAE9F2D21EEBQ45334689-DC7E26F7-4F31-427F-BE9D-5A1367AF595EQ45361447-697CE24B-10EF-47FF-B08D-1209BD98BF00Q45886829-75934868-589E-41DC-B5A9-7296FAB37DA7Q46446491-672C7740-91AE-4300-BC7D-0AF4B47B5B64Q50790069-F520176E-CD1C-410F-9D7A-EA1EFCD085A3Q50862966-FF6EC335-E777-480D-9AA8-42804B9563C6Q53085303-149DFBE5-F9E2-4A84-8DD2-45A88D5314BAQ53221793-4A89CAD2-8DF4-457F-A23A-F70E06C8BB65Q54478013-CC4603BD-6A80-4411-B49E-19F433659C21Q56995088-65857BC4-005F-4568-BE08-2DD106FC8DF3Q57209660-D1EFADF3-79CC-4606-A00C-95741C100D14Q58493309-3D55E5F4-82C8-4426-8A44-CFFF5BB04525Q67984055-0E75D4C5-CC98-4180-8332-CE38D5FB37E0Q68759752-B9003640-1D15-408C-81A5-243FFCE68B07Q69743036-2DF67661-E500-4233-8BB6-552CC592A8FDQ69841658-95328DD5-5B03-4B01-8EAE-D10253743843Q74162307-3CC87DED-5D92-4D0F-82E6-F10952E06C2A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Franco Narni
@ast
Franco Narni
@en
Franco Narni
@es
Franco Narni
@nl
type
label
Franco Narni
@ast
Franco Narni
@en
Franco Narni
@es
Franco Narni
@nl
prefLabel
Franco Narni
@ast
Franco Narni
@en
Franco Narni
@es
Franco Narni
@nl
P106
P1153
6603794171
P21
P31
P496
0000-0003-3994-9101